(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 27.78% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.3%.
Supernus Pharmaceuticals's revenue in 2026 is $830,438,000.On average, 7 Wall Street analysts forecast SUPN's revenue for 2026 to be $52,040,533,469, with the lowest SUPN revenue forecast at $48,932,482,084, and the highest SUPN revenue forecast at $54,319,693,649. On average, 7 Wall Street analysts forecast SUPN's revenue for 2027 to be $80,564,040,018, with the lowest SUPN revenue forecast at $56,588,390,966, and the highest SUPN revenue forecast at $146,189,437,695.
In 2028, SUPN is forecast to generate $98,757,795,087 in revenue, with the lowest revenue forecast at $63,416,571,183 and the highest revenue forecast at $162,058,112,244.